Druker BJ - Search Results

1

STI571: a gene product-targeted therapy for leukemia.

Mauro MJ, Druker BJ. Mauro MJ, et al. Among authors: druker bj. Curr Oncol Rep. 2001 May;3(3):223-7. doi: 10.1007/s11912-001-0054-z. Curr Oncol Rep. 2001. PMID: 11296132 Review.

2

Chronic myelogenous leukemia.

Mauro MJ, Druker BJ. Mauro MJ, et al. Among authors: druker bj. Curr Opin Oncol. 2001 Jan;13(1):3-7. doi: 10.1097/00001622-200101000-00002. Curr Opin Oncol. 2001. PMID: 11148678 Review.

3

STI571: targeting BCR-ABL as therapy for CML.

Mauro MJ, Druker BJ. Mauro MJ, et al. Among authors: druker bj. Oncologist. 2001;6(3):233-8. doi: 10.1634/theoncologist.6-3-233. Oncologist. 2001. PMID: 11423669 Free article. Review.

4

ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.

Mauro MJ, O'Dwyer ME, Druker BJ. Mauro MJ, et al. Among authors: druker bj. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S77-8. doi: 10.1007/s002800100310. Cancer Chemother Pharmacol. 2001. PMID: 11587372

5

Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.

O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, Lawce H, Mauro MJ, Maziarz RT, Braziel RM. O'Dwyer ME, et al. Among authors: druker bj. Leukemia. 2003 Mar;17(3):481-7. doi: 10.1038/sj.leu.2402848. Leukemia. 2003. PMID: 12646934

6

Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.

Sherbenou DW, Wong MJ, Humayun A, McGreevey LS, Harrell P, Yang R, Mauro M, Heinrich MC, Press RD, Druker BJ, Deininger MW. Sherbenou DW, et al. Among authors: druker bj. Leukemia. 2007 Mar;21(3):489-93. doi: 10.1038/sj.leu.2404554. Epub 2007 Jan 25. Leukemia. 2007. PMID: 17252009

7

Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors.

Bumm T, Deininger J, Newell AH, Lawce H, Olson S, Mauro M, Druker B, Deininger M. Bumm T, et al. Leukemia. 2010 Aug;24(8):1525-1528. doi: 10.1038/leu.2010.123. Epub 2010 Jun 10. Leukemia. 2010. PMID: 20535153 Free PMC article. No abstract available.

8

Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.

O'Dwyer ME, Druker BJ. O'Dwyer ME, et al. Among authors: druker bj. Curr Opin Oncol. 2000 Nov;12(6):594-7. doi: 10.1097/00001622-200011000-00013. Curr Opin Oncol. 2000. PMID: 11085460 Review.

9

STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.

O'Dwyer ME, Druker BJ. O'Dwyer ME, et al. Among authors: druker bj. Lancet Oncol. 2000 Dec;1:207-11. doi: 10.1016/s1470-2045(00)00149-2. Lancet Oncol. 2000. PMID: 11905636 Review.

10

An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.

Agarwal A, Eide CA, Harlow A, Corbin AS, Mauro MJ, Druker BJ, Corless CL, Heinrich MC, Deininger MW. Agarwal A, et al. Among authors: druker bj. Leukemia. 2008 Dec;22(12):2269-72. doi: 10.1038/leu.2008.124. Epub 2008 May 29. Leukemia. 2008. PMID: 18509354 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

441 results

Search Page

Filters